CELLDEX THERAPEUTICS INCORPORATED (CLDX)

Celldex Therapeutics (CLDX) is in focus after releasing topline results from its Phase 2 clinical trial in prurigo nodularis, a development that gives investors new information on a key pipeline program. See our latest analysis for Celldex Therapeutics. The Phase 2 readout arrives after a period ...

CareDx (NASDAQ:CDNA) reported second-quarter 2026 revenue growth of 52% as the transplant diagnostics company expanded testing services, completed the sale of its lab products business and began integrating the recently acquired NavDx specialty oncology platform. Total revenue rose to $132 million

CareDx (CDNA) delivered earnings and revenue surprises of +68.18% and +15.41%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

The Clorox Company CLX is scheduled to report fourth-quarter fiscal 2026 results on Aug. 3, after market close, and is likely to have registered declines in the top and bottom lines.The Zacks Consensus Estimate for revenues is pegged at $1.91 billion, indicating a drop of 4.1% from the prior-year ..…

The transaction is expected to ... transaction, CBIZ’s common stock will no longer be listed on the New York Stock Exchange, and CBIZ will become a private company. Cancellation of Earnings Conference Call and 2026 Financial Outlook...